Skip to main content
Top
Published in: Cancer Causes & Control 2/2019

01-02-2019 | Breast Cancer | Original Paper

Trends in lobular carcinoma in situ management: endocrine therapy use in California and New Jersey

Authors: Schelomo Marmor, Bonnie Jerome-D’Emilia, James W. Begun, Jane Yuet Ching Hui, Ariella M. Altman, Scott Kizy, Todd M. Tuttle

Published in: Cancer Causes & Control | Issue 2/2019

Login to get access

Abstract

Purpose

The diagnosis of lobular carcinoma in situ (LCIS) is a strong risk factor for breast cancer. Endocrine therapy (ET) for LCIS has been shown to decrease breast cancer risk substantially. The purpose of this study was to evaluate the trends of ET use for LCIS in two large geographic locations.

Patients and methods

We identified women, ages 18 through 75, with a microscopic diagnosis of LCIS in California (CA) and New Jersey (NJ) from 2004 to 2014. We evaluated trends in unadjusted ET rates during the study period and used logistic regression to evaluate the relationship between patient, tumor, and treatment characteristics, and ET use.

Results

We identified 3,129 patients in CA and 2,965 patients in NJ. The overall use of ET during the study period was 14%. For the combined sample, women in NJ were significantly less likely to utilize ET then their counterparts in CA (OR 0.77, CI 0.66–0.90, NJ vs. CA). In addition, patients in the later year period (OR 1.27, CI 1.01–1.59, 2012–2014 vs. 2004–2005) and women who received an excisional biopsy (OR 2.35, CI 1.74–3.17), were more likely to utilize ET. Uninsured women were less likely to receive ET (OR 0.61, CI 0.44–0.84, non-insured vs. insured status).

Conclusions

We observed that an increasing proportion of women are using ET for LCIS management, but geographical differences exist. Health insurance status played an important role in the underutilization of ET. Further research is needed to assess patient outcomes given the variations in management of LCIS.
Literature
1.
go back to reference King TA, Pilewskie M, Muhsen S, Patil S, Mautner SK, Park A, Oskar S et al (2015) Lobular carcinoma in situ: a 29-year longitudinal experience evaluating clinicopathologic features and breast cancer risk. J Clin Oncol 33:3945–3952CrossRefPubMedPubMedCentral King TA, Pilewskie M, Muhsen S, Patil S, Mautner SK, Park A, Oskar S et al (2015) Lobular carcinoma in situ: a 29-year longitudinal experience evaluating clinicopathologic features and breast cancer risk. J Clin Oncol 33:3945–3952CrossRefPubMedPubMedCentral
4.
go back to reference Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ et al (2017) NCCN guidelines insights: breast cancer, version 1.2017. J Natl Compr Cancer Netw 15(4):433–451CrossRef Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ et al (2017) NCCN guidelines insights: breast cancer, version 1.2017. J Natl Compr Cancer Netw 15(4):433–451CrossRef
6.
go back to reference Chuba PJ, Hamre MR, Yap J et al (2005) Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol 23:5534–5541CrossRefPubMed Chuba PJ, Hamre MR, Yap J et al (2005) Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol 23:5534–5541CrossRefPubMed
8.
go back to reference Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. JNCI 90(18):1371–1388CrossRefPubMed Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. JNCI 90(18):1371–1388CrossRefPubMed
9.
go back to reference Bambhroliya A, Chavez-MacGregor M, Brewster AM (2015) Barriers to the use of breast cancer risk reduction therapies. J Natl Compr Cancer Netw 13(7):927–935CrossRef Bambhroliya A, Chavez-MacGregor M, Brewster AM (2015) Barriers to the use of breast cancer risk reduction therapies. J Natl Compr Cancer Netw 13(7):927–935CrossRef
12.
go back to reference Jerome-D’Emilia B, Suplee PD, Akincigil A (2015) Validation of the Spanish version of the mammography specific self-efficacy scale. Oncol Nurs Forum 42(3):E279–E286CrossRefPubMed Jerome-D’Emilia B, Suplee PD, Akincigil A (2015) Validation of the Spanish version of the mammography specific self-efficacy scale. Oncol Nurs Forum 42(3):E279–E286CrossRefPubMed
14.
go back to reference Pesce CE, Liederbach E, Czechura T, Winchester DJ, Yao K (2014) Changing surgical trends in young patients with early stage breast cancer, 2003 to 2010: a report from the National Cancer Database. J Am Coll Surg 219(1):19Y28CrossRef Pesce CE, Liederbach E, Czechura T, Winchester DJ, Yao K (2014) Changing surgical trends in young patients with early stage breast cancer, 2003 to 2010: a report from the National Cancer Database. J Am Coll Surg 219(1):19Y28CrossRef
16.
go back to reference Smith SG, Sestak I, Forster A, Partridge A, Side L et al (2015) Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis. Ann Oncol 27(4):575–590CrossRefPubMedPubMedCentral Smith SG, Sestak I, Forster A, Partridge A, Side L et al (2015) Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis. Ann Oncol 27(4):575–590CrossRefPubMedPubMedCentral
17.
go back to reference Kinney AY, Richards C, Vernon SW, Vogel VG (1998) The effect of physician recommendation on enrollment in the breast cancer chemoprevention trial. Prev Med 27(5):713–719CrossRefPubMed Kinney AY, Richards C, Vernon SW, Vogel VG (1998) The effect of physician recommendation on enrollment in the breast cancer chemoprevention trial. Prev Med 27(5):713–719CrossRefPubMed
20.
go back to reference Hum S, Wu M, Pruthi S, Heisey R (2016) Physician and patient barriers to breast cancer preventive therapy. Curr Breast CA Rep 8(3):158–164CrossRef Hum S, Wu M, Pruthi S, Heisey R (2016) Physician and patient barriers to breast cancer preventive therapy. Curr Breast CA Rep 8(3):158–164CrossRef
22.
go back to reference Almeida RA, Dubay LC, Ko G (2001) Access to care and use of health services by low-income women. Health Care Financ Rev 22(4):27–47PubMedPubMedCentral Almeida RA, Dubay LC, Ko G (2001) Access to care and use of health services by low-income women. Health Care Financ Rev 22(4):27–47PubMedPubMedCentral
24.
go back to reference Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM et al (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. JNCI 97(22):1652–1662CrossRefPubMed Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM et al (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. JNCI 97(22):1652–1662CrossRefPubMed
25.
go back to reference Brewster AM, Christo DK, Lai H, Helzlsouer K (2005) Breast carcinoma chemoprevention in the community setting. Estimating risks and benefits. Cancer 15:1147–1153CrossRef Brewster AM, Christo DK, Lai H, Helzlsouer K (2005) Breast carcinoma chemoprevention in the community setting. Estimating risks and benefits. Cancer 15:1147–1153CrossRef
26.
go back to reference Kadakia KC, Henry NL (2015) Adjuvant endocrine therapy in premenopausal women with breast cancer. Clin Adv Hematol Oncol 13(10):663PubMedPubMedCentral Kadakia KC, Henry NL (2015) Adjuvant endocrine therapy in premenopausal women with breast cancer. Clin Adv Hematol Oncol 13(10):663PubMedPubMedCentral
27.
go back to reference Messalli EM, Scaffa C (2009) Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update. Int J Women’s Health 1:11CrossRef Messalli EM, Scaffa C (2009) Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update. Int J Women’s Health 1:11CrossRef
28.
go back to reference Takeuchi Y, Hamaya E, Taketsuna M, Sowa H (2015) Safety of 3-year raloxifene treatment in Japanese postmenopausal women aged 75 years or older with osteoporosis: a postmarketing surveillance study. Menopause 22(10):1134–1137CrossRefPubMed Takeuchi Y, Hamaya E, Taketsuna M, Sowa H (2015) Safety of 3-year raloxifene treatment in Japanese postmenopausal women aged 75 years or older with osteoporosis: a postmarketing surveillance study. Menopause 22(10):1134–1137CrossRefPubMed
30.
go back to reference Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, Fehrenbacher L, Lin Gomez S, Miles S, Neugut AI (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28(27):4120–4128CrossRefPubMedPubMedCentral Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, Fehrenbacher L, Lin Gomez S, Miles S, Neugut AI (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28(27):4120–4128CrossRefPubMedPubMedCentral
31.
go back to reference Bober SL, Hoke LA, Duda RB, Regan MM, Tung NM (2004) Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol 22(24):4951–4957CrossRefPubMed Bober SL, Hoke LA, Duda RB, Regan MM, Tung NM (2004) Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol 22(24):4951–4957CrossRefPubMed
32.
go back to reference Jerome-D’Emilia B, Begun JW (2005) Diffusion of breast conserving surgery in medical communities. Soc Sci Med 60(1):143–151CrossRefPubMed Jerome-D’Emilia B, Begun JW (2005) Diffusion of breast conserving surgery in medical communities. Soc Sci Med 60(1):143–151CrossRefPubMed
33.
go back to reference Shahbazi S, Woods SJ (2016) Influence of physician, patient, and health care system characteristics on the use of outpatient mastectomy. Am J Surg 211(4):802–809CrossRefPubMed Shahbazi S, Woods SJ (2016) Influence of physician, patient, and health care system characteristics on the use of outpatient mastectomy. Am J Surg 211(4):802–809CrossRefPubMed
34.
go back to reference Waljee JF, Hawley S, Alderman AK, Morrow M, Katz SJ (2007) Patient satisfaction with treatment of breast cancer: does surgeon specialization matter? J Clin Oncol 25(24):3694–3698CrossRefPubMed Waljee JF, Hawley S, Alderman AK, Morrow M, Katz SJ (2007) Patient satisfaction with treatment of breast cancer: does surgeon specialization matter? J Clin Oncol 25(24):3694–3698CrossRefPubMed
Metadata
Title
Trends in lobular carcinoma in situ management: endocrine therapy use in California and New Jersey
Authors
Schelomo Marmor
Bonnie Jerome-D’Emilia
James W. Begun
Jane Yuet Ching Hui
Ariella M. Altman
Scott Kizy
Todd M. Tuttle
Publication date
01-02-2019
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 2/2019
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-019-1126-4

Other articles of this Issue 2/2019

Cancer Causes & Control 2/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine